Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 17, 2018 09:00 ET | Source: Poseida Therapeutics, Inc.

Poseida Announces Initial Phase 1 Data for P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma

Low dose cohort completed with rapid and clear signs of efficacy in all three patients, and no cytokine release syndrome Data presented at the American Association for Cancer Research (AACR) Annual...
April 03, 2018 08:00 ET | Source: Poseida Therapeutics, Inc.

Poseida Raises $30.5 Million in Series B Financing

SAN DIEGO, April 03, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies,...
March 26, 2018 08:00 ET | Source: Poseida Therapeutics, Inc.

Poseida to Present P-BCMA-101 Phase 1 Data at the American Association for Cancer Research (AACR) Annual Meeting 2018

SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies,...
March 02, 2018 08:15 ET | Source: Fundamental Markets

Report: Exploring Fundamental Drivers Behind Accelerate Diagnostics, FTI Consulting, Spark Therapeutics, Achaogen, Oxford Industries, and Kronos Worldwide — New Horizons, Emerging Trends, and Upcoming Developments

NEW YORK, March 02, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders,...
February 28, 2018 08:00 ET | Source: Poseida Therapeutics, Inc.

Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer

SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies,...
February 23, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Participate in Multiple Conferences in March

PHILADELPHIA, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
February 20, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Reports 2017 Financial Results and Recent Business Progress

PHILADELPHIA, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
February 14, 2018 08:00 ET | Source: Poseida Therapeutics, Inc.

Poseida Therapeutics Presents Stem Cell Memory CAR-T Therapy for Prostate Cancer at 2018 Keystone Symposia on Emerging Cellular Therapies

SAN DIEGO, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies,...
February 13, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Host Conference Call on Tuesday, Feb. 20 at 8:30 a.m. ET to Discuss 2017 Results and Recent Business Highlights

PHILADELPHIA, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a...
February 05, 2018 08:00 ET | Source: Poseida Therapeutics, Inc.

Poseida Therapeutics Appoints Martin Giedlin, Ph.D., as Vice President, Technical Operations

SAN DIEGO, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies,...